Intellectual Property India Publishes Patent Application for 'A Multi-Antigenic Rna Sars-Cov-2 Vaccine And Associated Methods' Filed by Geneius Biotechnology, Inc.

MUMBAI, India, Aug. 1 -- Intellectual Property India has published a patent application (202517068094 A) filed by Geneius Biotechnology, Inc., Natick, U.S.A., on July 16, for 'a multi-antigenic rna sars-cov-2 vaccine and associated methods.'

Inventor(s) include Ryan, David James; Slanetz, Alfred E; Muzaffar, Farzonai; and Klietmann, Wolfgang Fritz.

The application for the patent was published on Aug. 1, under issue no. 31/2025.

According to the abstract released by the Intellectual Property India: "The present technology provides multivalent vaccine compositions and Tcell compositions comprising viral antigens and associated methods. In some embodiments, the viral antigens are SARS-CoV-2 antigens. The vaccine compositions and the T cell compositions may comprise each of a Spike (S) peptide, a VME1 (M) peptide, an NCAP (N) peptide, an ORF7a (7a) peptide, an ORF3a (3a) peptide, an ORF8 (8) peptide, and an Nsp6 peptide."

The patent application was internationally filed on Dec. 18, 2023, under International application No.PCT/US2023/084666.

Disclaimer: Curated by HT Syndication.